Computational Pathology Market (2025 - 2033)

Computational Pathology Market Summary

The global computational pathology market size was estimated at USD 682.48 million in 2024 and is projected to reach USD 1,447.62 million by 2033, growing at a CAGR of 9.0% from 2025 to 2033. The growth is attributed to the rising integration of machine learning and artificial intelligence (AI) technologies, the increasing demand for advanced solutions for faster diagnosis, the rising prevalence of chronic diseases, and increasing investment in healthcare by market players focused on developing advanced solutions.

The computational pathology market is predominantly propelled by the increasing incidence of chronic diseases, notably cancer. The high prevalence of cancer necessitates pathologists to utilize pathology data that can aid in tailoring personalized therapies for patients. Thereby, digital pathology is increasingly being preferred by pathologists, as it accelerates the rate of diagnosis, increases diagnostic accuracy, and provides therapeutic recommendations to improve patient outcomes. For instance, according to a study published in the Journal of Pathology in August 2023, deep learning and artificial intelligence (AI) algorithms to analyze and interpret histopathology images promises substantial improvements in diagnostic accuracy and efficiency, especially for cancer diagnosis and prognosis.

The incorporation of machine learning and AI technologies into pathology workflows significantly transforms the diagnostic process. For instance, in October 2024, Proscia introduced digital pathology toolkits designed to facilitate the development of AI models. These tools enable life science researchers to convert biopsy slide images into quantitative data for training foundation models, improving biomarker discovery, and diagnostics. The development of such solutions enables the rapid and accurate analysis of images, allowing pathologists to identify patterns that may indicate disease progression. By automating routine tasks, AI enables pathologists to focus on more complex diagnostic challenges, thereby improving efficiency and accuracy. This shift enhances diagnostic precision and supports the development of personalized medicine through predictive modeling.

The computational pathology market holds substantial opportunities driven by significant factors. Advances in artificial intelligence (AI), machine learning (ML), and digital imaging are transforming pathological workflows, enabling faster, more precise analysis of tissue slides and providing critical insights into disease diagnosis and prognosis. This technological progress is addressing the growing demand for rapid, accurate diagnostics, owing to the rising global prevalence of chronic diseases such as cancer and cardiovascular conditions.

Moreover, increasing adoption of telepathology is expanding remote expert consultations and improving healthcare access, especially in underserved regions. Integrating digital health systems enhances laboratory efficiency, automates routine tasks, and allows pathologists to focus on complex diagnostics, fostering greater accuracy and personalized medicine development. Furthermore, rising investments by healthcare providers and industry players in developing AI-powered pathology solutions stimulates innovation and market growth.

Market Concentration & Characteristics

The computational pathology market is experiencing a high degree of innovation driven by several interrelated advancements such as Machine Learning (ML), Deep Learning, Natural Language Processing (NLP) models, and Computer Vision. The adoption of ML algorithms has enabled pathologists to enhance diagnostic accuracy through predictive analytics. These algorithms analyze vast datasets to identify patterns that may be overlooked by human eyes, thereby facilitating earlier and more precise cancer detection.

This transition to automated systems has significantly reduced the time required for diagnosis, improving workflow efficiency in clinical settings. For instance, In June 2024, Mindpeak GmbH expanded its AI portfolio with a new prostate cancer AI software co-developed with Clinsight AB. The software analyzes digital histopathology images of prostate needle biopsies, detects suspicious areas, and grades malignancies using Gleason scoring.

The level of M&A activities is moderate in the market. Mature players are acquiring emerging players to strengthen their position. For instance, in July 2025, Quanterix completed its acquisition of Akoya Biosciences, creating the first integrated platform for ultra-sensitive detection of blood- and tissue-based protein biomarkers.

Increasing government support in the form of approvals is encouraging companies to invest in technological advancements and expansion strategies. For instance, in March 2025 Epredia received U.S. FDA 510(k) clearance for the E1000 Dx, a high-speed, automated whole-slide imaging scanner with advanced software capable of digitizing up to 1,500 tissue samples daily.

The geographical expansion drives the growth by enhancing access to advanced solutions in various geographical locations globally. For instance, in April 2022, Crosscope Inc. partnered with Waleed Pharmacy & Stores LLC to introduce AI-enabled digital pathology solutions in Oman. This collaboration aims to enhance cancer diagnostics and care in response to the rising cancer incidence in the region. Waleed Pharmacy will represent Crosscope in Oman, leveraging its expertise to advance healthcare IT solutions.

Case Study: AI-Enhanced Detection of High-Risk Prostate Cancer with Aiforia Prostate Cancer Suite

Challenge:

Prostate cancer diagnosis is complex, with pathologists needing to review 10-18 biopsy specimens per patient. Identifying high-risk features like perineural invasion (PNI) and cribriform pattern 4 is time-consuming, subject to inter-observer variability, and critical for accurate risk stratification.

Solution:

Aiforia’s Prostate Cancer Suite integrates AI models into digital pathology to detect PNI and cribriform patterns alongside Gleason grading. The system provides pixel-level overlays, transparent outputs, and automated data extraction directly into LIS, reducing manual errors and streamlining workflows.

Outcomes:

• 34% faster slide review time with >96% cancer recall rate.

• 92.6% accuracy in PNI detection and 91.3% for cribriform pattern 4.

• Improved reproducibility, reduced missed lesions, and enhanced diagnostic confidence.

• CE-IVD validation ensures reliability while supporting scalability and future feature expansions.

Component Insights

Software segment dominated the market and held the largest revenue share of 66.5% in 2024, owing to its positive impact on clinical workflows and diagnostic processes. Rising demand for precision medicine, coupled with increasing adoption of digital pathology scanners and whole-slide imaging (WSI), is driving the growth of software solutions, as they allow seamless integration of digital workflows, predictive analytics, and standardized reporting across laboratories and hospitals. In June 2025, ASCO 2025 highlighted AI-powered digital pathology software advancing cancer diagnostics and risk prediction. Proscia’s Concentriq platform improved accuracy in breast, colon, lung, and prostate cancer assessments, streamlining workflows and supporting precision medicine through computational pathology.

Services segment is expected to witness the fastest growth over the forecast period, owing to the increasing demand for remote services and telepathology solutions. The outsourcing of computational pathology tasks is becoming a trend driven by the need for cost-effective and scalable solutions. As healthcare institutions encounter challenges such as a shortage of trained pathologists, they are turning to service providers that offer specialized expertise and advanced technologies, thereby contributing to the segment’s growth.

Application Insights

Disease diagnosis segment dominated the market with a revenue share of 46.2% in 2024. Computational pathology is transforming disease diagnosis by enabling pathologists to analyze digital slides with unprecedented precision and consistency. Advanced AI algorithms can detect cellular abnormalities, quantify tissue features, and recognize disease-specific patterns that may be subtle or missed during manual evaluation. This capability reduces diagnostic errors, improves reproducibility across laboratories, and allows pathologists to focus on complex cases requiring expert judgment. In January 2025, an article published in the Journal of Pathology Informatics discussed advances in computational pathology, highlighting how digital whole-slide imaging and AI-powered analysis enhance disease diagnosis, improve workflow efficiency, and support precision medicine through integrated molecular and imaging data.

Academic research segment is expected to witness the fastest CAGR over the forecast period. The growth is attributed to the increasing emphasis on precision medicine and personalized healthcare, which drives the demand for advanced analytical techniques for understanding complex biological data. Academic institutions are driving innovation through research initiatives that leverage computational pathology tools to analyze large datasets.

Technology Insights

Machine Learning (ML) segment accounted for the largest revenue share in 2024 as these technologies help enhance diagnostic accuracy and efficiency through advanced data analysis. Machine learning in the computational pathology market is driving advancements in diagnostic accuracy, workflow efficiency, and disease characterization. Machine learning algorithms, including supervised, unsupervised, and deep learning models, are applied to whole slide images (WSIs) to detect patterns, classify tissue types, and quantify biomarkers. These systems enable automated feature extraction and analysis, reducing inter-observer variability and supporting standardized pathology reporting. Integration with multi-omics datasets further enhances the predictive and prognostic capabilities of these models. The demand for machine learning solutions is rising due to their ability to handle large-scale datasets with high throughput and precision.

Natural Language Processing (NLP) models segment is expected to witness the fastest growth driven by their ability to enhance diagnostic accuracy and streamline workflows. The integration of NLP allows for the effective analysis of unstructured medical data, such as pathology reports. This capability helps pathologists gather relevant information from vast datasets, improving the speed and precision of diagnoses.

End Use Insights

Hospitals and diagnostic labs held the largest revenue share in 2024. Hospitals and diagnostic labs are major adopters of computational pathology, using AI-driven image analysis, digital slide management, and automated reporting to boost diagnostic accuracy and efficiency. Integration with laboratory information systems ensures seamless data flow, while whole-slide imaging supports remote collaboration. In February 2024, Qritive partnered with Metropolis Healthcare, Rajiv Gandhi Cancer Institute, and CŌRE Diagnostics in India to deploy its Pantheon image management system and AI pathology tools, achieving up to a 90% reduction in diagnosis time and an 80% drop in pathologist discordance.

Biotechnology and pharmaceutical companies are expected to witness the fastest growth over the forecast period. These companies are leveraging advanced computational techniques to enhance drug discovery and development processes. By integrating AI and ML algorithms into workflows, allows them to analyze vast amounts of data more efficiently, leading to faster identification of biomarkers and therapeutic targets. In addition, the rising demand for personalized medicine necessitates precise diagnostic tools, enabling personalized treatment plans based on individual patient needs.

Regional Insights

North America Computational Pathology Marketdominated the global market and accounted for the largest revenue share of 45.7% in 2024. This can be driven by the integration of AI-based diagnostics, strong digital infrastructure, and high investment in clinical research. For instance, major U.S. cancer centers are deploying deep learning models for tumor classification and biomarker quantification, improving diagnostic accuracy and enabling personalized treatment strategies. Partnerships between AI developers, diagnostic labs, and pharmaceutical companies are expanding applications in clinical trials and drug development. In March 2025, Aiforia partnered with PathPresenter to accelerate adoption of digital pathology and AI in the U.S., integrating Aiforia’s AI-powered image analysis with PathPresenter’s workflow platform. This collaboration enables pathologists to access advanced AI models for cancers such as breast, lung, and prostate, improving diagnostic speed and accuracy.

U.S. Computational Pathology Market Trends

Computational pathology market in the U.S. accounted for the largest share in 2024. One of the key factors driving the market growth is the high adoption rate of these solutions in the country, owing to their wide range of applications, from disease diagnosis to academic research. Moreover, the increasing efforts and investments in research to further enhance the application of computational pathology are further driving the market growth. For instance, in April 2024, the University of Pittsburgh and UPMC launched the computational pathology and AI Center of Excellence (CPACE) at the UPMC Cancer Pavilion, which aims to unite experts in these solutions and artificial intelligence to foster collaboration and innovation in medical research. CPACE focuses on utilizing AI to enhance disease detection and personalized treatment plans, ultimately improving patient care and outcomes.

Europe Computational Pathology Market Trends

The Europe computational pathology market is poised for significant growth driven by increasing demand for advanced diagnostic tools across a growing healthcare infrastructure and rising prevalence of chronic and complex diseases. Enhanced awareness of precision medicine and expanded access to cutting-edge pathology services are fueling the adoption of AI-powered computational pathology solutions. The region also benefits from strong investment in healthcare digitization and supportive regulatory frameworks that encourage innovation and integration of digital diagnostics.

The computational pathology market in Germany is expanding due to a robust healthcare infrastructure, advanced research in digital diagnostics, and strong technological innovation. Rising cancer incidence and chronic diseases drive demand for precise and efficient pathological analysis, increasing adoption of computational pathology solutions. University hospitals and pathology centers collaborate with industry to develop and implement AI-powered tools. Digital slide scanning and AI-driven image analysis platforms improve workflow and diagnostic accuracy. In October 2024, nearly 40 AI-assisted pathology products with CE marking became available for routine clinical use in Germany, targeting key cancer diagnostics such as breast, prostate, and lung cancers.

The UK computational pathology market is primarily driven by the NHS’s commitment to modernizing diagnostic services through digital transformation. There is a growing emphasis on improving diagnostic speed and accuracy to support personalized medicine, especially in oncology. Initiatives under the NHS Long Term Plan prioritize expanding digital infrastructure and integrating AI powered pathology tools across pathology networks to enhance efficiency and patient outcomes

Asia Pacific Computational Pathology Market Trends

Computational pathology market in Asia Pacific is expected to register the fastest growth rate over the forecast period. The region has seen a rise in the incidence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. According to the Global Cancer Observatory (GLOBOCAN 2022), around 9,826,539 people were diagnosed with cancer in 2022, with lung, breast, and colorectum cancer being the leading cancer types. This has led to a growing demand for efficient diagnostic tools and increased adoption of these solutions for disease detection, grading, and research. Moreover, the increasing investments and increasing awareness about the advantages of technologically advanced solutions are further contributing to the market growth.

The computational pathology market in China is propelled by the country’s aggressive push toward healthcare digitization and the escalating integration of artificial intelligence in diagnostic workflows. Faced with a rapidly aging population and soaring rates of chronic diseases such as cancer, China urgently requires scalable solutions that enhance diagnostic precision and alleviate pathologist shortages. Computational pathology promises to revolutionize diagnostic accuracy and workflow efficiency by harnessing AI-powered image analysis. In April 2022, an article published in Gland Surgery reviewed advances in computational pathology in China, focusing on deep learning applications in digital breast cancer diagnosis. The study highlighted how AI-driven models, especially convolutional neural networks, have enhanced diagnostic accuracy, classification, and prognostic predictions by automating complex image analysis.

India Computational Pathology Marketis witnessing a strong growth, driven by the increasing awareness of the benefits of digital diagnostics. The surge of cancer and chronic diseases, and government initiatives to modernize healthcare infrastructure drive the the growth of computational pathology market in India. The shortage of trained pathologists and the need for faster, more accurate diagnoses increase adoption of AI-powered digital pathology solutions. The growing burden of cancer and infectious diseases creates demand for scalable platforms capable of handling large volumes of complex histopathological data.

Latin America Computational Pathology Market Trends

The computational pathology market in Latin America is driven by growing adoption of digital pathology and whole-slide imaging (WSI), enabling pathologists to capture, store, and analyze high-resolution tissue images. Increasing integration of AI and machine learning enhances diagnostic accuracy, reduces human error, and accelerates workflow efficiency.

Middle East & Africa Computational Pathology Market Trends

Computational pathology market in MEA is driven by increasing healthcare digitization, rising adoption of AI-driven diagnostic tools, and expanding healthcare infrastructure. Government initiatives to modernize healthcare systems, coupled with growing awareness of precision medicine, are driving demand for advanced pathology solutions. In addition, the region's focus on improving cancer diagnosis and treatment is further fueling the adoption of computational pathology technologies, contributing to market expansion.

Key Computational Pathology Company Insights

Key companies are adopting strategies such as mergers and acquisitions, product and service launches, agreements, joint ventures, collaborations, and expansion to strengthen their position in the market.

Recent Developments

• In June 2025, FUJIFILM Healthcare Europe and Ibex Medical Analytics partnered to integrate Ibex’s AI cancer diagnostics platform with Fujifilm’s SYNAPSE Pathology solution. The initial rollout begins at North Bristol NHS Trust UK, which is anticipated to offer AI tools for prostate, breast, and gastric cancer diagnostics to healthcare providers globally.

"Ibex is committed to ensuring our customers can easily integrate our AI tools into their diagnostic workflows, helping them to provide accurate and timely cancerdiagnoses to their patients. We're thrilled to partner withFujifilmand provide streamlined workflows to North Bristol NHS and customers around the world."
- Stuart Shand, Chief Commercial Officer, Ibex Medical Analytics

• In May 2024, Microsoft collaborated with the University of Washington, and Providence Health aims to address key challenges in implementing AI for cancer diagnostics, leveraging significant scale. The researchers have developed a machine learning model, which Providence describes as one of the most extensive AI training initiatives in real-world whole-slide tissue analysis.

“This transformative work is the result of focused efforts to overcome three major challenges that have stymied previous computational pathology models from widely being applied in the clinical setting: shortage of real-world data, inability to incorporate whole-slide modeling and lack of accessibility,”

-Providence’s chief analytics and research officer

• In March 2023, Aiosyn launched AiosynQC, an AI-powered automated quality control solution designed to enhance digital pathology workflows in research, diagnostics, and pharmaceuticals. This product represents the first in Aiosyn's suite of workflow solutions, aiming to facilitate the integration of computational pathology algorithms into standard practices, thereby enhancing diagnostic precision and quality.

“AiosynQC will be an important foundational layer and we believe that AI-powered workflow solutions are the entry point for the use and adoption of computational pathology algorithms.”

-Patrick de Boer, CEO of Aiosyn

• In November 2022, Visiopharm launched Phenoplex, a unified, easy-to-use AI-driven multiplex tissue image analysis workflow. Integrated into their Oncotopix Discovery platform, it supports major multiplex formats, enabling interactive biomarker visualization, cellular phenotyping, and spatial analysis without coding.

• In May 2021, Quest Diagnostics partnered with Paige.ai for developing AI-driven digital pathology cancer diagnostics. Paige's computational platform uses machine learning to extract diagnostic information from pathology slides, helping pathologists analyze images more quickly and accurately. The collaboration focuses on developing software for diagnosing solid tumors in lung cancer, prostate, and colorectal breast patients and aims to deliver insights to improve cancer diagnosis and make precision medicine more accessible and actionable.

“As the leader in advanced diagnostics, we are excited to actively participate in the creation and use of new technologies that further the mission to make precision medicine clinically accessible, actionable and economical. We are energized about contributing our expertise to Paige’s computational pathology leadership to deliver insights from leading-edge technologies to improve the diagnosis of cancer and other diseases.”

- General Manager, Oncology Franchise, Quest Diagnostics.

Computational Pathology Market